There is a strong focus at this year's CPhI on education. Once again the Pre-show Conference Series offers insight from a number of eminent speakers on Oct. 24, but newly introduced is the Lunchtime Education Series, which has been expanded from the early morning sessions from previous years.
There is a strong focus at this year’s CPhI on education. Once again the Pre-show Conference Series offers insight from a number of eminent speakers on Oct. 24, but newly introduced is the Lunchtime Education Series, which has been expanded from the early morning sessions from previous years.
The Pre-Show Conference Series offers two tracks of three modules. Track one’s modules include global API sourcing (current and future trends, sourcing challenges and considerations), contract partnership selection (changing structures, strategic alliances, risk mitigation), and supplier and partner management in emerging markets (CMO management, ensuring quality of service)—all with Q&A panel discussions. Track two is more forward facing, with modules on the strategic operational future of the pharma industry (drug innovation and big pharma’s role, positive trends), biosimilar and biobetter challenges and opportunities (key growth markets, post-patent opportunity, regulatory challenges), and market growth in generics (power shift towards generics, role and growth of emerging markets). Once again, Q&A panel discussions conclude each module.
The Lunchtime Education Series runs from 12:00 to 15:30 on each day of the event, with topics spread over six workshops, each with its own dedicated leader. The topics are diverse but follow a similar theme in providing industry examples and case studies to aid in the learning process. As an example, on Oct. 24, Workshop 3 has a technical focus and covers innovation and development in drug delivery, in particular parenteral nanosuspensions. Topics include stabilisation of nanoparticles, pre-clinical characterisation, production scale-up—always of interest, and sterility assurance. But it’s not all hard work: breaking up each day’s pair of workshops is a “networking lunch” giving you chance not only to eat, but to discuss topics with like-minded individuals.
We’ll see you there!
For more information on both series, visit www.cphi.com.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.